Lates News

According to AI Quick News, Dongwu Securities issued a research report on March 30th, giving a "buy" rating to Zejing Pharmaceutical (688266.SH). The main reasons for the rating include: 1) a broad market opportunity for expanding its differentiated pipeline and creating long-term competitive advantages; 2) continued commercialization expansion, building a diversified product matrix. (Daily Economic News)